{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lu X"],"funding":["Fondation ARC"],"pagination":["134"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12062415"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (p = 0.048). Complete responses were exclusively observed in cluster1/2 (p = 0.012), with longer progression-free survival (p = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies."],"journal":["NPJ precision oncology"],"pubmed_title":["Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma."],"pmcid":["PMC12062415"],"funding_grant_id":["SIGNIT"],"pubmed_authors":["Xu L","Vano YA","Lu X","Sautes-Fridman C","Malouf GG","Verkarre V","Cheng W","Kotti S","Oudard S","Sun CM","Fridman WH","Su X","Yan F"],"additional_accession":[]},"is_claimable":false,"name":"Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma.","description":"In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (p = 0.048). Complete responses were exclusively observed in cluster1/2 (p = 0.012), with longer progression-free survival (p = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-01T22:22:15.979Z","creation":"2026-05-22T03:08:15.805Z"},"accession":"S-EPMC12062415","cross_references":{"pubmed":["40341678"],"doi":["10.1038/s41698-025-00912-x"]}}